САРТАНЫ ВТОРОГО ПОКОЛЕНИЯ: РАСШИРЕНИЕ ТЕРАПЕВТИЧЕСКИХ ВОЗМОЖНОСТЕЙ

С. В. Недогода

Статья

САРТАНЫ ВТОРОГО ПОКОЛЕНИЯ: РАСШИРЕНИЕ ТЕРАПЕВТИЧЕСКИХ ВОЗМОЖНОСТЕЙ

С. В. Недогода

2011

https://doi.org/10.20996/1819-6446-2011-7-4-477-482

Проанализированы особенности применения блокатора рецепторов ангиотензина II телмисартана с учетом его клинико-фармакологических характеристик. Особое внимание уделено преимуществам телмисартана перед другими сартанами. Подробно рассмотрены особенности взаимодействия телмисартана с рецепторами, активирующими пролиферацию пероксисом (peroxisome proliferator-activated receptors, PPAR). Характер взаимодействие с этими рецепторами лежит в основе фармакодинамических эффектов представителей различных групп лекарственных препаратов. С учетом представленных данных сделан вывод о существенных преимуществах антигипертензивной терапии с применением телмисартана.

Недогода С. В. САРТАНЫ ВТОРОГО ПОКОЛЕНИЯ: РАСШИРЕНИЕ ТЕРАПЕВТИЧЕСКИХ ВОЗМОЖНОСТЕЙ. Рациональная Фармакотерапия в Кардиологии. 2011;7(4):477-482. https://doi.org/10.20996/1819-6446-2011-7-4-477-482

Цитирование

Список литературы

1. Kjeldsen S., Naditch-Brule L., Perlini S. et al. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardio-metabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 2008; 26: 2064–70.

2. Ram C. Angiotensin receptor blockers: current status and future prospects. Am J Med 2008; 121: 656–63.

3. Nixon R.M., Muller E., Lowy A., Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract 2009; 63 (5): 766-775.

4. Song JC, White CM. Olmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertension. Formulary 2001; 36: 487–499.

5. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001;61(10):1501-29.

6. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355(9204):637-45.

7. Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 2002;16 Suppl 2:S13-6.

8. Differences Among Angiotensin II Receptor Blockers. US Pharm 2004;10:HS19- HS25.

9. Kakuta H et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25: 41–51.

10. Nedogoda S.V. Hyperuricaemia and kidney damage in patients with hypertension and metabolic syndrome. Quality of life. Kachestvo zhizni. Meditsina 2008; 3: 16-27. Russian (Недогода С.В. Гиперурикемия и поражение почек у больных с артериальной гипертензией и метаболическим синдромом. Качество жизни. Медицина 2008; 3: 16-27).

11. Benson S, Pershadsingh H, Ho C et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgammamodulating activity. Hypertension 2004; 43 (5): 993–1002.

12. Schupp M., Janke J., Clasen R. et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054–7.

13. Babaev V., Ishiguro H., Ding L. et al. Macrophage expression of peroxisome proliferator-activated receptor α reduces atherosclerosis in low density lipoprotein receptor deficient mice. Circulation 2007; 116: 1404–1412.

14. Cresci S. PPAR genomics and pharmacogenomics: implications for cardiovascular disease. PPAR Res 2008;2008:374549.

15. Duan S.Z., Ivashchenko C.Y., Russell M.W. et al.Cardiomyocyte-specffic knockout and agonist of per-oxisome proliferator-aVolctivated receptor-γ both induce cardiac hypertrophy in mice. Circulation Research 2005; 97(4): 372–379.

16. Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 2006; 5:789–801.

17. Fogo A.B. Potential for peroxisome proliferatoractivated receptor-agonists in progression: beyond metabolism. Current Opinion in Nephrology and Hypertension 2008; 17(3):282–285.

18. Kurtz T.W. Beyond the classic angiotensin-receptor blocker profile. Nature Reviews Cardiology 2008;5:S19–S26.

19. Kurtz T., Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009; 32 (10): 826–34.

20. Bagry H.S., Raghavendram S., Carli F. Metabolic syndrome and insulin resistance. Anesthesiology 2008;108(3):506–523.

21. Leone T., Weinheimer C., Kelly D. A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999; 96: 7473–7478.

22. Li X., Hansen P.A., Xi L. et al. Distinct mechanisms of glucose lowering by specific agonists for per-oxisomal proliferator activated receptor gamma and retinoic acid X receptors. J Biol Chem 2005; 280(46): 38317–38327.

23. Sugimoto K., Qi N.R., Kazdová L. et al. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006;47(5):1003-9.

24. Matchar D.B., McCrory D.C., Orlando L.A. et al. Systematic Review: Comparative Effectiveness of An-giotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension. Ann Intern Med 2008;148:16–29.

25. Quinn C.E., Hamilton P.K., Lockhart C.J. Thiazolidinediones: effects on insulin resistance and the cardiovascular system. British J Pharmacology 2008; 153: 636–645.

26. Miura Y., Yamamoto N., Tsunekawa S. et al. Metabolic Effects of Replacing Valsartan or Candesartan by Telmisartan. Diabetes Care 2005; 28(3): 757–8.

27. Vitale C., Mercuro G., Castiglioni C. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005;4:6.

28. Derosa G., Ragonesi P.D., Mugellini A. et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a ran-domized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004;27(7):457-64.

29. van Zwieten P.A. Angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans): similarities and differences. Neth Heart J 2006; 14(11):381–387.

30. Sugawara A., Takeuchi K., Uruno A. at al. Negative regulation of rat thromboxane receptor gene by 15- deoxy-D12, 14-PGJ2 and troglitazone by activating PPAR-g in vascular smooth muscle cells. J Am Soc Nephrol 1998; 9: 358A.

31. Ayuko Nakano, Yoshiyuki Hattori, Chie Aoki et al. Telmisartan inhibits cytokine-induced nuclear factor-kB activation independently of the peroxisomeproliferators-activated receptor-α. Hypertension Research 2009;32: 765–769.

32. McGill J.B., Reilly P.A. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001;23(6):833-50.

33. Sharma A., Davidson J., Koval S., Lacourcière Y. Telmisartan/hydrochlorothiazide versus valsar-tan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovascular Diabetology 2007; 6:28-36.

34. Hsueh W.A., Quinones M.J. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003;92:10J–17J.

35. Yusuf S., Teo K., Anderson C. et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008; 372: 1174–83.

36. Yusuf S., Diener H., Sacco R. et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225–37.

Документы

Информация

Автор

С. В. Недогода Волгоградский государственный медицинский университет.

Название журнала

Рациональная Фармакотерапия в Кардиологии

Ключевые слова

Статья